mapatumumab

mAbexperimental

Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody undergoing clinical trials for the treatment of cancer. It targets TRAIL-R1, also known as DR4, which is expressed on the surface of many tumor cell types. — Wikipedia

Clinical trial activity

7 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 2004 (NCT00094848)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hgs-etr1
  • mapatumumab
  • mapatumumab
  • trail-r1 mab
  • trm-1
  • trm-1
  • trm-1 hgs-etr1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01258608Phase 2Feb 1, 2011GlaxoSmithKline, Human Genome Sciences
NCT01088347Phase 1/Phase 2 (Phase 2)Mar 1, 2010Human Genome Sciences, University of Groningen
NCT00712855Phase 1Jun 1, 2008GlaxoSmithKline, Human Genome Sciences
NCT00583830Phase 2Jan 1, 2007GlaxoSmithKline, Human Genome Sciences
NCT00315757Phase 2May 1, 2006GlaxoSmithKline, Human Genome Sciences
NCT00092924Phase 2Sep 24, 2004GlaxoSmithKline, Human Genome Sciences
NCT00094848Phase 2Jun 1, 2004GlaxoSmithKline, Human Genome Sciences
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Human Genome SciencesFor profit7622004
GlaxoSmithKlineFor profit6022004
University of GroningenAcademic/Hospital1112010
3 organizations
Page 1 / 1